Detail akcie ALX Oncology Rg online

Business Summary: ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.
Financial Summary: BRIEF: For the three months ended 31 March 2025, ALX Oncology Holdings Inc revenues was not reported. Net loss decreased 14% to $30.8M. Lower net loss reflects Reserach and developement decrease of 36% to $13.3M (expense), Stock-based Compensation in R&D decrease of 40% to $3M (expense), Interest expense - Balancing value decrease of 8% to $351K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.71 to -$0.58.